147 related articles for article (PubMed ID: 9192926)
1. An evaluation of two aerosol delivery systems for rhDNase.
Shah PL; Scott SF; Geddes DM; Conway S; Watson A; Nazir T; Carr SB; Wallis C; Marriott C; Hodson ME
Eur Respir J; 1997 Jun; 10(6):1261-6. PubMed ID: 9192926
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
[TBL] [Abstract][Full Text] [Related]
3. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
[TBL] [Abstract][Full Text] [Related]
4. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers.
Cipolla D; Gonda I; Shire SJ
Pharm Res; 1994 Apr; 11(4):491-8. PubMed ID: 8058603
[TBL] [Abstract][Full Text] [Related]
5. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
6. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
7. Crossover Evaluation of Compressors and Nebulizers Typically Used by Cystic Fibrosis Patients.
Awad SM; Berlinski A
Respir Care; 2018 Mar; 63(3):294-300. PubMed ID: 29432139
[TBL] [Abstract][Full Text] [Related]
8. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer.
Johnson JC; Waldrep JC; Guo J; Dhand R
Respir Care; 2008 Dec; 53(12):1703-8. PubMed ID: 19025706
[TBL] [Abstract][Full Text] [Related]
9. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal evaluation of compressor/nebulizer performance.
Awad S; Williams DK; Berlinski A
Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
[TBL] [Abstract][Full Text] [Related]
11. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols.
Coates AL; MacNeish CF; Meisner D; Kelemen S; Thibert R; MacDonald J; Vadas E
Chest; 1997 May; 111(5):1206-12. PubMed ID: 9149571
[TBL] [Abstract][Full Text] [Related]
12. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis.
Geller D; Thipphawong J; Otulana B; Caplan D; Ericson D; Milgram L; Okikawa J; Quan J; Bowman CM
J Aerosol Med; 2003; 16(2):175-82. PubMed ID: 12823911
[TBL] [Abstract][Full Text] [Related]
13. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
15. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
16. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice.
Wong-Beringer A; Lambros MP; Beringer PM; Johnson DL
Chest; 2005 Nov; 128(5):3711-6. PubMed ID: 16304338
[TBL] [Abstract][Full Text] [Related]
17. Characterization of aerosol output from various nebulizer/compressor combinations.
Reisner C; Katial RK; Bartelson BB; Buchmeir A; Rosenwasser LJ; Nelson HS
Ann Allergy Asthma Immunol; 2001 May; 86(5):566-74. PubMed ID: 11379809
[TBL] [Abstract][Full Text] [Related]
18. RhDNase I aerosol deposition and related factors in cystic fibrosis.
Diot P; Palmer LB; Smaldone A; DeCelie-Germana J; Grimson R; Smaldone GC
Am J Respir Crit Care Med; 1997 Nov; 156(5):1662-8. PubMed ID: 9372691
[TBL] [Abstract][Full Text] [Related]
19. Where we are now with rhDNase.
Geddes DM; Shah PL
Lancet; 1999 May; 353(9166):1727. PubMed ID: 10347981
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
